About: Ipilimumab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ipilimumab Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	Class
rdfs:label	Ipilimumab
rdfs:subClassOf	Antibodies, Monoclonal nodeID://b646221 nodeID://b646222 nodeID://b646223 nodeID://b646224
Has_Target	CTLA-4 Antigen
Concept_In_Subset	FDA Established Names and Unique Ingredient Identifier Codes Terminology
Semantic_Type	Amino Acid, Peptide, or Protein Immunologic Factor
Preferred_Name	Ipilimumab
NSC_Code	720801 732442
UMLS_CUI	C1367202
CAS_Registry	477202-00-9
Accepted_Therapeutic_Use_For	Unresectable or Metastatic Melanoma
In_Clinical_Trial_For	Stage III or IV Melanoma; After Allogenic Stem Cell Transplantation of Patients with Persistent or Progressive Cancer; Ovarian Epithelial Cancer; Acute Myeloid Leukemia; Myelodysplastic Syndrome. Colon Cancer or Prostate Cancer Refractory to Vaccine Therapy; Metastatic Clear Cell Renal Cancer Patients Who are Refractory to or Ineligible for Interleukin-2. Non-Small Cell Lung Cancer Previously Treated with Sargramostim-Based Autologous Tumor Vaccine; Metastatic Androgen-Independent Prostate Cancer; Metastatic Melanoma; Follicular or Mantle Cell Lymphoma.
FDA_UNII_Code	6T8C155666
Contributing_Source	FDA
ALT_DEFINITION	A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells.NCI-GLOSS
PDQ_Open_Trial_Search_ID	38447
PDQ_Closed_Trial_Search_ID	38447
Legacy_Concept_Name	Anti-Cytotoxic_T-Lymphocyte-Associated_Antigen-4_Monoclonal_Antibody
FULL_SYN	ipilimumabPTNCI-GLOSSCDR0000535555 MDX-010PTNCI-GLOSSCDR0000438727 YervoyBRNCI MDX-010CNNCI IPILIMUMABPTFDA6T8C155666 MDX-CTLA4ABNCI Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal AntibodySYNCI IpilimumabPTNCI
DEFINITION	A fully human monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.NCI
code	C2654
is someValuesFrom of	nodeID://b646209 nodeID://b646211 nodeID://b646217 nodeID://b646219

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software